About Psoriasis Cure Now

Psoriasis Cure Now (PCN) launched in 2005 with a mission to increase research funding for psoriasis and psoriatic arthritis, to educate opinion leaders and the general public about the seriousness of psoriatic disease, and to inspire and support patients and their loved ones to live their best lives despite psoriasis. Founded and run by a psoriasis patient, Psoriasis Cure Now has been aided by the hard work and financial support of hundreds of volunteers across the United States. We are a 501(c)(3) nonprofit organization.

Focused primarily on those with moderate to severe psoriasis and/or psoriatic arthritis, PCN leverages its ability to target, nimbly, areas where the psoriasis community has unmet needs. Our scrappy, unconventional vision of patient advocacy makes us willing to shake up the status quo when the status quo is not adequately serving psoriasis patients.

Prior to launching Psoriasis Cure Now, its founder and president, Michael Paranzino, worked at the intersection of policy, politics, and communications; as Chief of Staff and Legislative Director to a Member of Congress, as a lobbyist for the US solar energy industry, and as a communications consultant and policy advocate. He has also practiced law; worked on political campaigns; and been interviewed hundreds of times for print, radio and television. He holds degrees from Yale University and the NYU School of Law. Four members of his extended family also have psoriasis, giving him, as he puts it, “plenty of skin in the game” – and the motivation to seek swift progress for the psoriasis community. Reach him directly at: michaelp@psoriasiscurenow.org.

If you would like to assist us, be it once a year or more frequently, we would love your help. Sign up on our Volunteer page and we will find a way to leverage your talents and passion to advance the mission we share.

Volunteer with Us

The Latest Psoriasis News

“Fail first” insurance mandates not just a problem for U.S. psoriasis patients

“Fail first” policies are one of the mandates imposed by some U.S. health insurers to reduce their costs. They require that people with psoriasis (and other serious diseases) try older and inferior – and often less safe – treatments before they can access the 21st century treatments that work best. Continue Reading…

Imagine knowing after 4 weeks, how a new psoriasis treatment would be working for you after 6 months…

Here’s an interesting, after-the-fact analysis from clinical trials of the biologic Ilumya (tildrakizumab-asmn), an “IL-23 inhibitor” marketed by Sun Pharma. The researchers looked at psoriasis severity scores used in clinical trials, known as PASI scores (Psoriasis Area and Severity Index), for each patient. Each patient’s score is determined before the Continue Reading…

Opioid use “substantial” among people with moderate to severe psoriasis

A recent study looked at a database of privately insured people that included about 9,000 psoriasis patients, of whom just over 2,000 were identified as having moderate to severe psoriasis. It found that about 25% of those 2,000 received opioids, compared to 16% of otherwise-comparable people without psoriasis. The figure Continue Reading…

Join the Battle